Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session

NEXT STORY
Roche launches the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision medicine
PREV STORY
PM360 2021 Innovative Company CureClick
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session

NEXT STORY
Roche launches the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision medicine
PREV STORY
PM360 2021 Innovative Company CureClick
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aptose Reports Results for the Third Quarter 2021

author_avatar
NASDAQ Market News

TLC Earns Highest Ranking in Corporate Governance Evaluation Seven Years Running

author_avatar
NASDAQ Market News

Tonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine Programs

author_avatar
NASDAQ Market News